Rome Therapeutics debuts with $50M and Rosana Kapeller at the helm

As GV's first entrepreneur-in-residence, Rosana Kapeller, Ph.D., incubated Rome Therapeutics. (Rome Therapeutics)

In 2018, Rosana Kapeller left Nimbus Therapeutics, the company she built from the ground up, “to do something different.” Two years and a stint at GV later, she’s unveiling that something: Rome Therapeutics, a new biotech startup looking to drug parts of the human genome previously spurned as “junk DNA.”

The company starts life with $50 million in series A capital from GV, Arch Venture Partners and Partners Innovation Fund. Its mission? To go beyond the 2% of the genome that codes directly for proteins in search of new drug targets for cancer and autoimmune disease. It’s looking at parts of the genome called the repeatome, made up of—you guessed it—repeating sequences of nucleic acids, called repeats for short.

Once considered to have no function, the repeatome has only recently become accessible, thanks to advancements in technology, Kapeller told FierceBiotech.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

RELATED: 2019’s Fiercest Women in Life Sciences | Rosana Kapeller—GV

“People started understanding the role of repeats, that we shouldn’t be focused only on proteins as targets, but on RNA, and that RNAs have functions beyond just coding for proteins,” she added.

The company hopes that the repeats will hold the key to longer-lasting treatments for cancer and autoimmune disease.

“We think repeats can help us better understand diseases and also conquer and control them. The reason for that is a lot of those repeats look like viruses,” Kapeller said, adding that it’s a result of ancient viruses becoming integrated into human DNA over hundreds of millions of years. “So, they must play a role in human health and now we know they play a role in human disease.”

These viruslike strands of genetic material stay dormant in healthy cells, but when cells undergo stress—during circumstances like an infection, cancer or autoimmune disease—they “wake up” and may play a role in the development of that disease.

In the case of cancer, when a cell goes from healthy to malignant, DNA repeats switch on and get transcribed into RNA—which looks at lot like virus RNA. This calls forth a response from the innate immune system to come and quash the cancer cells.

But, being “quite smart,” the cancer cells can modify the viruslike RNA, making it into DNA that becomes part of the cancer cell’s genome, Kapeller said. This slashes the amount of RNA so that it’s no longer activating the immune response, and the cancer cells can grow and spread. But this defense mechanism could turn out to be cancer’s undoing.

That virus-like DNA got incorporated into the human genome during evolution, but it’s expressed only in sick cells and not in healthy cells, Kapeller said. It could be a way to zero in on tumor cells while sparing healthy tissues.

Rome has picked out some targets to pursue in cancer and autoimmune disease but is keeping specific indications under wraps. It’s got a few years of “pretty traditional drug discovery” ahead of it, identifying and generating small-molecule modulators of its targets and then testing them in lab dishes and animal models in both disease areas.

“We’re not disclosing timelines right now,” Kapeller said. After all, Rome wasn’t built in a day.

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.